The clinical successes of CAR-T therapy have been linked to the ability of CAR-T cells to proliferate and survive within the patient's body . Favorable outcomes depend on the persistence of CAR-T cells after initial infusion. Sustained persistence ensures that T cells remain active to mount an effective immune response, thus providing long-term protection against malignancies. The longer CAR-T cells can expand and remain cytotoxic, the stronger the anti-tumor response and the higher the likelihood of achieving remission and patient survival. Considering that cancer is a long-term challenge, the duration of the immune response is even more important. Thus, this review paper will explore strategies to increase persistence.